Global Nucleic Acid Based Therapeutics Market 2023
Description
The Nucleic Acid Based Therapeutics Market is poised for significant growth, with a projected expansion from USD 4.28 billion in 2022 to USD 9.51 billion by 2029, reflecting a robust compound annual growth rate (CAGR) of 11.6% during the forecast period of 2023-2029. This market primarily revolves around the development and utilization of nucleic acid therapeutics for the treatment of various diseases. Notable examples of nucleic acid-based therapeutics include aptamers, antisense oligonucleotides (ASOs), and small interfering RNAs (siRNAs), which are designed to specifically target and suppress disease-related genes. ASOs and siRNAs, in particular, have demonstrated their efficacy in silencing genes by interfering with mRNA translation and nuclear DNA transcription.
The demand for nucleic acid-based therapeutics has witnessed a significant surge, driven by their successful application in the treatment of COVID-19. Research has shown promising results in utilizing these therapeutics to suppress viral gene expression, offering potential avenues for combating viral infections. Globally, there are currently over 400 RNA-targeting drug development projects underway, indicating a strong growth trajectory for the market throughout the forecast period.
The increasing prevalence of genetic diseases necessitates the development of innovative treatment approaches, and nucleic acid-based therapeutics offer a promising solution by targeting and correcting abnormal gene expression. Additionally, investments in healthcare infrastructure and research and development activities, along with collaborations between pharmaceutical companies and academic institutions, further drive market growth. The pharmaceutical industry's focus on developing innovative biologics, including nucleic acid-based therapeutics, also contributes to the expansion of the market.
Market Segmentation
The market is segmented based on product type, application, end-user, and geography.
Segmentation by Product Type
RNA interference (RNAi) and short interfering RNAs (siRNAs)
Antisense Oligonucleotides (ASOs)
Others
Segmentation by Application
Autoimmune Disorders
Infectious Diseases
Genetic Disorders
Cancer
Others
Segmentation by End-User
Hospitals and Clinics
Academic and Research Institutes
Segmentation by Geography
North America %li%United States, Canada, Mexico
Europe %li%United Kingdom, Germany, France, Italy, Spain, and Rest of Europe
Asia-Pacific %li%China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific
Latin America %li%Brazil, Argentina, and Rest of Latin America
Middle East and Africa %li%GCC, South Africa, and Rest of Middle East and Africa
Antisense oligonucleotides (ASOs) selectively bind to specific mRNA sequences, degrading or inhibiting their translation into protein. ASOs show promise for treating genetic disorders, infectious diseases, and cancer. Approved ASO therapies like Spinraza, Exondys51, Onpattro, and Tegsedi demonstrate this approach's success. The ASOs segment is expected to grow due to increased demand, R&D activities, and new product introductions. Business strategies like partnerships and acquisitions drive growth, resulting in the availability of more ASO products and increased company activities.
North America is expected to hold a significant market share due to growing research on nucleic acid-based therapies, increasing prevalence of genetic and chronic disorders, and rising investments in research and development. The demand for nucleic acid-based therapies is driven by the prevalence of autoimmune diseases and the burden of cancer. Market growth is further supported by innovative product launches, approvals, partnerships, acquisitions, expansions, and collaborations in the region.
Competitive Landscape
The nucleic acid-based therapeutics market is moderately fragmented, with numerous global and regional players actively researching and developing therapeutics for chronic, genetic, and infectious diseases. Notable participants include Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Biogen Inc., Ionis Pharmaceuticals Inc., Moderna Inc., Novartis AG, Sarepta Therapeutics Inc., Silence Therapeutics PLC, Stoke Therapeutics Inc., and Wave Life Sciences Ltd.
Recent Industry Developments
In March 2023, Ionis Pharmaceuticals received FDA approval for potential accelerated approval of Tofersen for SOD1-ALS treatment. Tofersen reduces SOD1 protein synthesis.
In February 2023, Myeloid Therapeutics Inc. collaborated with the NSW Government in Australia to establish a GMP manufacturing facility for RNA immunotherapies. The facility will expedite commercialization of Myeloid's RNA therapeutics and promote RNA ecosystem growth in NSW.
Why Buy This Report?
Get a detailed picture of the Global Nucleic Acid Based Therapeutics Market
Identify segments/areas to invest in over the forecast period in the Global Nucleic Acid Based Therapeutics Market
Understand the competitive environment, the market’s leading players
The market estimate for ease of analysis across scenarios in Excel format
Strategy consulting and research support for three months
Print authentication provided for the single-user license
The Nucleic Acid Based Therapeutics Market is poised for significant growth, with a projected expansion from USD 4.28 billion in 2022 to USD 9.51 billion by 2029, reflecting a robust compound annual growth rate (CAGR) of 11.6% during the forecast period of 2023-2029. This market primarily revolves around the development and utilization of nucleic acid therapeutics for the treatment of various diseases. Notable examples of nucleic acid-based therapeutics include aptamers, antisense oligonucleotides (ASOs), and small interfering RNAs (siRNAs), which are designed to specifically target and suppress disease-related genes. ASOs and siRNAs, in particular, have demonstrated their efficacy in silencing genes by interfering with mRNA translation and nuclear DNA transcription.
The demand for nucleic acid-based therapeutics has witnessed a significant surge, driven by their successful application in the treatment of COVID-19. Research has shown promising results in utilizing these therapeutics to suppress viral gene expression, offering potential avenues for combating viral infections. Globally, there are currently over 400 RNA-targeting drug development projects underway, indicating a strong growth trajectory for the market throughout the forecast period.
The increasing prevalence of genetic diseases necessitates the development of innovative treatment approaches, and nucleic acid-based therapeutics offer a promising solution by targeting and correcting abnormal gene expression. Additionally, investments in healthcare infrastructure and research and development activities, along with collaborations between pharmaceutical companies and academic institutions, further drive market growth. The pharmaceutical industry's focus on developing innovative biologics, including nucleic acid-based therapeutics, also contributes to the expansion of the market.
Market Segmentation
The market is segmented based on product type, application, end-user, and geography.
Segmentation by Product Type
RNA interference (RNAi) and short interfering RNAs (siRNAs)
Antisense Oligonucleotides (ASOs)
Others
Segmentation by Application
Autoimmune Disorders
Infectious Diseases
Genetic Disorders
Cancer
Others
Segmentation by End-User
Hospitals and Clinics
Academic and Research Institutes
Segmentation by Geography
North America %li%United States, Canada, Mexico
Europe %li%United Kingdom, Germany, France, Italy, Spain, and Rest of Europe
Asia-Pacific %li%China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific
Latin America %li%Brazil, Argentina, and Rest of Latin America
Middle East and Africa %li%GCC, South Africa, and Rest of Middle East and Africa
Antisense oligonucleotides (ASOs) selectively bind to specific mRNA sequences, degrading or inhibiting their translation into protein. ASOs show promise for treating genetic disorders, infectious diseases, and cancer. Approved ASO therapies like Spinraza, Exondys51, Onpattro, and Tegsedi demonstrate this approach's success. The ASOs segment is expected to grow due to increased demand, R&D activities, and new product introductions. Business strategies like partnerships and acquisitions drive growth, resulting in the availability of more ASO products and increased company activities.
North America is expected to hold a significant market share due to growing research on nucleic acid-based therapies, increasing prevalence of genetic and chronic disorders, and rising investments in research and development. The demand for nucleic acid-based therapies is driven by the prevalence of autoimmune diseases and the burden of cancer. Market growth is further supported by innovative product launches, approvals, partnerships, acquisitions, expansions, and collaborations in the region.
Competitive Landscape
The nucleic acid-based therapeutics market is moderately fragmented, with numerous global and regional players actively researching and developing therapeutics for chronic, genetic, and infectious diseases. Notable participants include Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Biogen Inc., Ionis Pharmaceuticals Inc., Moderna Inc., Novartis AG, Sarepta Therapeutics Inc., Silence Therapeutics PLC, Stoke Therapeutics Inc., and Wave Life Sciences Ltd.
Recent Industry Developments
In March 2023, Ionis Pharmaceuticals received FDA approval for potential accelerated approval of Tofersen for SOD1-ALS treatment. Tofersen reduces SOD1 protein synthesis.
In February 2023, Myeloid Therapeutics Inc. collaborated with the NSW Government in Australia to establish a GMP manufacturing facility for RNA immunotherapies. The facility will expedite commercialization of Myeloid's RNA therapeutics and promote RNA ecosystem growth in NSW.
Why Buy This Report?
Get a detailed picture of the Global Nucleic Acid Based Therapeutics Market
Identify segments/areas to invest in over the forecast period in the Global Nucleic Acid Based Therapeutics Market
Understand the competitive environment, the market’s leading players
The market estimate for ease of analysis across scenarios in Excel format
Strategy consulting and research support for three months
Print authentication provided for the single-user license
PART 1. INTRODUCTION
1.1 Description
1.2 Objectives of The Study
1.3 Market Segment
1.4 Years Considered for The Report
1.5 Currency
1.6 Key Target Audience
PART 2. RESEARCH METHODOLOGY
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
PART 5. GLOBAL NUCLEIC ACID BASED THERAPEUTICS MARKET BY PRODUCT TYPE
5.1 Antisense oligonucleotides (ASOs)
5.2 RNA interference (RNAi) and short interfering RNAs (siRNAs)
5.3 Others
PART 6. GLOBAL NUCLEIC ACID BASED THERAPEUTICS MARKET BY APPLICATION
6.1 Autoimmune disorders
6.2 Cancer
6.3 Genetic disorders
6.4 Infectious diseases
6.5 Others
PART 7. GLOBAL NUCLEIC ACID BASED THERAPEUTICS MARKET BY END USER
7.1 Academic and research institutes
7.2 Hospitals and clinics
PART 8. GLOBAL NUCLEIC ACID BASED THERAPEUTICS MARKET BY GEOGRAPHY
8.1 North America
8.2 Europe
8.3 Asia Pacific
8.4 Latin America
8.5 Middle East and Africa
PART 9. COMPANY PROFILES
9.1 Alnylam Pharmaceuticals Inc.
9.2 Arrowhead Pharmaceuticals Inc.
9.3 Biogen Inc.
9.4 Ionis Pharmaceuticals Inc.
9.5 Moderna, Inc.
9.6 Novartis AG
9.7 Sarepta Therapeutics Inc.
9.8 Silence Therapeutics PLC
9.9 Stoke Therapeutics, Inc.
9.10 Wave Life Sciences Ltd.
DISCLAIMER
1.1 Description
1.2 Objectives of The Study
1.3 Market Segment
1.4 Years Considered for The Report
1.5 Currency
1.6 Key Target Audience
PART 2. RESEARCH METHODOLOGY
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
PART 5. GLOBAL NUCLEIC ACID BASED THERAPEUTICS MARKET BY PRODUCT TYPE
5.1 Antisense oligonucleotides (ASOs)
5.2 RNA interference (RNAi) and short interfering RNAs (siRNAs)
5.3 Others
PART 6. GLOBAL NUCLEIC ACID BASED THERAPEUTICS MARKET BY APPLICATION
6.1 Autoimmune disorders
6.2 Cancer
6.3 Genetic disorders
6.4 Infectious diseases
6.5 Others
PART 7. GLOBAL NUCLEIC ACID BASED THERAPEUTICS MARKET BY END USER
7.1 Academic and research institutes
7.2 Hospitals and clinics
PART 8. GLOBAL NUCLEIC ACID BASED THERAPEUTICS MARKET BY GEOGRAPHY
8.1 North America
8.2 Europe
8.3 Asia Pacific
8.4 Latin America
8.5 Middle East and Africa
PART 9. COMPANY PROFILES
9.1 Alnylam Pharmaceuticals Inc.
9.2 Arrowhead Pharmaceuticals Inc.
9.3 Biogen Inc.
9.4 Ionis Pharmaceuticals Inc.
9.5 Moderna, Inc.
9.6 Novartis AG
9.7 Sarepta Therapeutics Inc.
9.8 Silence Therapeutics PLC
9.9 Stoke Therapeutics, Inc.
9.10 Wave Life Sciences Ltd.
DISCLAIMER
